N/A N=375 Observational Study On Compliance Of Statin Treatment Of Patients With High Blood Cholesterol Levels
Dyslipidemia
Primary: Percentage of Participants Who Were Compliant With Statin Treatment — 86.7 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=257 Compliance With Treatment For Patients With Hyperlipidemia
Hyperlipidemia
Primary: Percentage of Participants With Positive Response on Increased Motivation Using a Self-test at Month 12 — 36.2 Percentage of participants
N/A N=60 Smart Capsule for Automatic Adherence Monitoring
Medication Adherence
Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)
N/A N=50 Effects of Use of a Connected Pillbox On Medication Adherence
Diabetes Mellitus · Hypertension · Hyperlipidemia
Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05
N/A N=5,421 Medication Adherence Clinical Decision Support
Hyperlipidemia · Hypertension · Diabetes
Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103
Phase 4 N=154 Self-management of Low Molecular Weight Heparin Therapy
Thromboembolism
Primary: Drug Use Problems — 1.25; 0.86; 1.20; 1.17 scores on a scale
Phase 4 N=262 Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia
Dyspepsia · Compliance · Depression
Primary: Compliance of Flupentixol-Melitracen — 44; 28; 31 participants
N/A N=153 Non-compliance on Treatment Among Diabetic Students at Sohag University
Diabetes Mellitus, Type 1
Primary: Distribution of Participants Responses as Regards DSMQ Glucose Management Domain — 13; 56; 39; 45 Participants
N/A N=40 Assessing the Effectiveness and Safety of the ID-Cap System for Medication Monitoring and Adherence
Medication Adherence
Primary: Medication Adherence — 94.8; 82.8 percentage of doses taken
N/A N=58 Impact on Instructional Video on Patients' Compliance With Preparation During CT Planning for Prostate Cancer
Latent Cancer (Prostate)
Primary: Number of Participants Whom Had Proper Preparation After Education Intervention — 22; 22; 7; 7 participants
Phase 4 N=197 Impact of Physician Directed Education on Patient Compliance With Hepatitis C Therapy
Chronic Hepatitis C · Genotype 1
Primary: Treatment Duration Compliance Rate — 85.4; 83.8 Percentage of compliance — p=0.4864
N/A N=75 Patient-Centered Medication Adherence Intervention for Schizophrenia
Schizophrenia
Primary: Antipsychotic Medication Adherence — 63.9; 75.0 percentage of participants — p=0.03
N/A N=15 Impact of Pillboxes on Medical Adherence
Chronic Disease · Medication Adherence
Primary: Medication Adherence at 1 Month — 11.83; 10.20; 9.33 score on a scale
N/A N=438 Interventions to Improve Specialty Medication Adherence
Adherence, Medication · Nonadherence, Medication
Primary: Median Proportion of Days Covered (PDC) at 8-months Post-enrollment — 0.94; 0.88 proportion of days covered (PDC) — p=0.001
N/A N=130 Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes
Acute Coronary Syndrome (ACS)
Primary: Adherence to Refills and Medications Scale (ARMS) — 12.03; 12.18 units on a scale
N/A N=294 Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Hepatitis C, Chronic · Hepatitis C
Primary: Number of Participants Who Are Triple-80 Compliant — 183 Participants
N/A N=60 Behavioral Economics to Improve Antihypertensive Therapy Adherence
Hypertension · Medication Adherence
Primary: Electronically Measured Mean Medication Adherence During Intervention — 87; 95; 92 Percentage of Timely Med Adherence
N/A N=62 Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial
Rheumatic Diseases · Gout · Adherence, Medication
Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78
N/A N=165 Intervention to Improve Inhalative Adherence
Chronic Asthma · COPD
Primary: Time to Next Asthma or COPD Exacerbation up to 182 Days — 172; 161 days to first exacerbation
N/A N=476 Behavioral Economic Strategies to Improve PRO Adherence
Cancer
Primary: PRO Adherence — 50.0; 56.9; 34.9 pct. assigned questionnaires completed
N/A N=67 Outcomes of Compliance With Brace Wear in Clubfoot
Clubfoot
Primary: Wear Rate Percentage (Number of Hours Per Day Brace Was Worn Out of the Recommended 24 Hours) — 91.7; NA; NA; 86.8 percentage of time worn
N/A N=253 Patient-Centered Adherence Intervention After Acute Coronary Syndrome (ACS) Hospitalization
Acute Coronary Syndrome
Primary: Adherence to Cardioprotective Medications (Clopidogrel, Statins, Beta Blockers, ACE-inhibitor/ARB) — 89.3; 73.9 percentage of participants — p=0.003
N/A N=72 Improving Medication Compliance and Smoking Cessation Treatment Outcomes for African American Smokers
Smokers
Primary: Percent Compliance With Chantix — 90.7; 85.8; 87.1; 91.7 Percentage of Participants
N/A N=102 Encouraging Patient-Centered Communication in Clinical Video Telehealth Visits
Diabetes Mellitus
Primary: HgbA1c — 8.5; 8.5; 7.99; 8.2 percentage of glycated hemoglobin
N/A N=200 Does a Patient Education Video Augment Pelvic Floor Physical Therapy Compliance?
Patient Compliance · Pelvic Floor Disorders
Primary: Number of Participants With Completed PT Visits — 47; 50; 11; 21 Participants — p=0.17
N/A N=40 Heart Failure Medication Adherence
Heart Failure
Primary: Adherence to Medication — 2; 3 Participants
N/A N=61 Increasing Adherence to Treatment Recommendations Following a Cardiac Event
Cardiovascular Disease
Primary: Participation in CR — 7; 11; 6 Participants
N/A N=746 Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)
Hepatitis C · Chronic Hepatitis C
Primary: Number of Participants With Biometrical Adherence to Therapy — 406; 415; 413 Participants
Phase 4 N=138 Adherence Study in COPD Patients
Chronic Obstructive Pulmonary Disease (COPD
Primary: Mean Number of Adherent Sets of Symbicort Puffs Per Day Over the 26-Week Study Period — 1.3; 1.6 Adherent sets of puffs / day — p=<0.001
N/A N=106 The Role of Apathy in Glycemic Control
Apathy · Diabetes
Primary: Change in HbA1c Over Baseline — -1.0; -0.1 percentage of HbA1c